• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Mobile MIM’s long, strange trip

Mobile MIM’s long, strange trip

February 10, 2011 By MedCity News

MobileMIM

It took nearly three years and three 510(k) applications, but MIM Software finally won Food & Drug Administration clearance for its Mobile MIM app, the first-ever mobile radiology app to receive the agency’s seal of approval.

The process was so fraught with confusion and miscommunication — or worse, no communication — that MIM CTO Mark Cain likened the experience to falling into a "black hole."

If there’s any good news for other radiology app developers, it’s that Beachwood, Ohio-based MIM’s experience might — might — provide a roadmap of sorts for the FDA to follow in reviewing similar apps for mobile devices like the iPhone and iPad in the future. And that’s no small point for a health IT industry that’s suffering from a lack of clarity when it comes to knowing what the FDA wants from developers of medical apps, many of which fall under the FDA’s jurisdiction because they’re considered medical devices.

"Clearance of this technology is a big step toward [the FDA] developing a model to review the next technology that comes down the pike. And there will be a next technology," said Bradley Merrill Thompson, a regulatory attorney with Epstein Becker & Green in Washington, D.C. (Thompson has written extensively on the intersection of regulation and mobile health technology, and his white paper (PDF) on the topic is highly recommended to anyone who wants to learn more on the subject.)

It’s not as if developing clear requirements for mHealth technology is an easy job for the FDA. The agency has already cleared a handful of apps, including one for heart monitoring and another for obstetrics, but a radiology app, whose success would be completely dependent on its ability to accurately present complex images, presented new challenges. Plus, the agency may be short on the experience and expertise needed to properly evaluate such a new form of technology.

An FDA spokeswoman declined an interview request because the agency is still refining its process for reviewing mobile apps.

"Clearance of Mobile MIM’s radiology app does not imply a generalized policy for mobile health devices," she said.

Still, the health IT industry no doubt hopes that clearance of the app will at least help the FDA formulate some sort of generalized policy for mobile apps. And with 80 percent of physicians expected to be using smart phones by 2012, the sooner that policy becomes clear, the better.

The Mobile MIM story

MIM Software has been developing radiology software since 2001, but as of early 2008, it hadn’t jumped into the mobile app market. That changed in March of that year, when — on a whim — two developers wrote the first lines of code for what would become the Mobile MIM app.

"It wasn’t part of our business plan. It just happened," said Cain. "Two of our employees began writing the code just to see if they could do it."

About two months later, the company had a working app, which shrinks the size of radiology images like CT and PET scans, transfers them securely and preserves image intensity values.

Knowing the app would be considered a medical device because doctors would use it to make diagnoses, MIM decided to make it available for free via Apple’s AppStore, hoping that the app wouldn’t draw FDA scrutiny because the company wasn’t trying to profit from it.

That’s not how things worked out. A few months later, Cain said, MIM received a notice about the app from the FDA saying, in effect, "Pull it now or our compliance department will be calling you shortly." The company wasted no time following those instructions.

"At that period of time, there were so many unknowns that the level of complexity was beyond our understanding," Cain said.

MIM then prepared and submitted a 510(k) application, which, if cleared, would have given MIM the right to begin marketing the app. From Cain’s perspective, the FDA’s response to 510(k) No. 1 left a lot to be desired. The agency questioned the company extensively about Apple’s iPhone hardware, about which the software company knew little.

"We got all these questions that didn’t make any sense," Cain said. "The communication breakdown was remarkable."

With both the FDA and MIM apparently unsure of how to proceed, the first bid for Mobile MIM clearance fizzled. MIM went "back to the drawing board," collected some clinical data and submitted it in another 510(k) in the summer of 2009. Radio silence. — MIM heard nothing from the agency, Can recalled.

"There was no communication, no feedback, no questions," he said. "We’d call and ask about it and we’d get, ‘No questions. It’s still under review.’"

That second application languished for 221 days. Then, in early 2010, the FDA told MIM that the bid would be rejected,a dding that the 510(k) route was the wrong protocal anyway. Lacking a "substantially equivalent" predicate device, the company would have to go through the more stringent pre-market approval program, which requires far more (and sometimes clinical) data and is thus a much more lengthy and expensive path.

After pondering its choices, MIM wound up appealing the FDA’s decision. In the summer of 2010, signs of progress began to appear. Reversing course, the federal watchdog agency said a 510(k) was the way to go after all, based this time on a prior version of MIM’s imaging software.

"There was a turn-around that summer," Cain said. "The communication was fantastic."

The company submitted 510(k) No. 3 in late 2010. The FDA cleared the app last week, stressing that it’s not intended to replace a full workstation but can be used to make a diagnosis when a physician does not have access to a workstation.

Cain expects the app to hit the AppStore this week for free at first. Radiologists will still to pay for the copmpany’s software to upload images to it.

Lessons learned

To hear Cain tell it, not much changed on MIM’s end. Throughout its dealings with the FDA, MIM made only one significant design change to the app, an adjustment to its "contrast response" that would compensate for possible hardware changes in subsequent versions of mobile devices, he said.

The majority of the FDA’s concerns all along were related to hardware, which Cain admits represents "a paradigm change" for the field of radiology. How does transferring a large image to a small screen affect a radiologist’s ability to discern subtle details? Is a consumer-oriented hardware device adequate for displaying complex medical images?

"You’re taking a consumer-grade instrument and you’re trying to show that it’s reliable enough to be used in a medical setting," said Thompson, the regulatory attorney. "There’s a lot to that."

Cain attributed the FDA’s ultimate decision to clear the app to two things: Personnel changes, which brought "new opinions and perspectives," and mounting pressure for the agency to provide more clarity to mHealth software developers.

"I’d like to say the [resulting] experience was purely because they decided to be transparent, but I think the pressure was on to finally accomplish this," he said. "It had gone on long enough. The medical world needed to understand the FDA’s viewpoint on portable technology in general."

The uncertainty surrounding the FDA’s regulation of mobile health apps is indicative of a "culture clash" between the Rockville, Md.-based agency and software developers’ Silicon Valley ethos, according to Thompson. The regulatory process is moving "very fast in Rockville terms, but very slow in Silicon Valley terms," he said.

"Silicon Valley is just not used to working in the public health environment, so it’s a difficult learning curve," Thompson explained.

At this point, there’s more pressure on the FDA than the software industry. The agency must fulfill its mission to protect public health without hampering the innovation that’s key for economic growth.

That means a host of questions without easy answers. What exactly, for example, should trigger FDA review of a mobile app? Should the FDA regulate apps that focus on general wellness, say for diabetes management or weight loss? If a networked device presents the wrong data, which vendor in that chain should be held responsible (imagine a mobile app on a device connected to a server, which in turn is connected to a doctor’s PC, which hosts desktop software)?

These questions will ultimately be decided by the agency, most likely after a period of public review. Until that happens, Cain said, there’s one practical thing developers looking to the medical app market can do: Make sure to have another source of income.

"For small developers, facing the black hole of the FDA process is tough," he said. "We were fortunate that we had an existing means to sustain our business during the drought."

Filed Under: Digital Health, News Well, Software / IT Tagged With: MIM Software

In case you missed it

  • DTW Podcast: How is Zimmer Biomet waging the ortho data war? Do medical devices carry physics-based biases?
  • Another BD Alaris infusion pump recall is Class I
  • 9 medical devices you should keep an eye out for in 2021
  • A quick history of the tech behind J&J, AstraZeneca’s COVID-19 vaccines
  • FDA finalizes rule to scale back how it regulates medtech software
  • Qorvo wins FDA nod for test that uses acoustic waves to detect COVID-19 antigens
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • SeaSpine prices $87.8M offering
  • Annual COVID-19 vaccines likely, according to Pfizer CEO
  • Medtronic has another serious HVAD recall
  • Vicarious Surgical to go public in $1.1B SPAC deal
  • Analysts are bullish on Align Technology
  • Trice Medical raises more than $10M
  • FDA clears Acutus Medical suite of universal transseptal crossing devices
  • Mayo Clinic helps launch two new companies for improved diagnostics
  • HHS shoots down ‘flawed’ plan to let some devices skip review
  • Solo-Dex launches peripheral nerve block catheter

RSS From Medical Design & Outsourcing

  • EPA delayed notifying residents of ethylene oxide emissions
    The EPA delayed notifying neighbors of an Illinois medical device sterilization plant of ethylene oxide (EtO) emissions the agency measured in 2018, according to an inspector general’s report released yesterday. The report also says that “leadership” in the agency’s Office of Air and Radiation also failed to conduct public meetings with residents either near the… […]
  • 9 medical devices you should keep an eye out for in 2021
    The medical device industry weathered the COVID-19 pandemic well — and is now set to roll out a host of innovations in 2021. Economists generally expect the U.S. to see a boom as we emerge from the pandemic and resulting recession. Medtech companies appear set to ride the wave this year, with plans to seek… […]
  • Greenlight Guru to provide QMS to NIH diagnostics program
    NIH has chosen Greenlight Guru to provide quality management software for its COVID-19 rapid diagnostics program. The agency launched the Rapid Acceleration of Diagnostics (RADx) program in March 2020 to speed the development, commercialization and implementation COVID-19 testing technologies. As the only QMS provider currently available to all projects in the RADx program, Greenlight Guru… […]
  • MicroCare names CFO
    MicroCare (New Britain, Conn.) has announced the appointment of John Stardellis as the company’s new chief financial officer (CFO). Stardellis joins MicroCare with more than 20 years’ experience in a variety of finance, policy and operational leadership roles. Most recently, he served as CFO at i-Health, a division of DSM Nutritional Products. “John’s track record with… […]
  • Mayo Clinic helps launch two new companies for improved diagnostics
    Mayo Clinic announced that it is introducing a new technology platform to support two new companies it has launched. Rochester, Minn.–based Mayo Clinic’s Remote Diagnostics & Management Platform (RDMP) is designed to connect data with new AI algorithms and augment human decision-making within existing clinical workflows, according to a news release. Get the full story… […]
  • Intertek gains FDA nod for premarket device testing
    Intertek has won accreditation under an FDA pilot program for testing laboratories, the company said this week. The accreditation authorizes Intertek’s 12 “medical centers of excellence” to perform premarket testing of devices for the U.S. market. The Accreditation Scheme for Conformity Assessment pilot program is a voluntary program developed to provide increased confidence in testing… […]
  • HHS shoots down ‘flawed’ plan to let some devices skip review
    The Biden administration has nixed what it described as a “flawed” Trump-era decision to exempt certain medical devices — including infusion pump controllers and fetal monitors — from regulatory review. HHS published the original notice in the Federal Register on Jan. 15, shortly before President Joe Biden was set to take office, without speaking with… […]
  • More than 50 medtech testing sites win FDA pilot accreditation
    The FDA announced today that more than 50 laboratory sites were chosen to participate in its program for streamlined regulatory reviews. In total, 53 sites made the FDA’s initial list for participation in its Accreditation Scheme for Conformity Assessment (ASCA) program, which will set out to support more streamlined regulatory reviews of medical device market… […]
  • Medline Industries up for sale?
    Medline Industries is looking for a buyer in a deal that could be worth $30 billion, according to a report in the Wall Street Journal. The Journal cites “people familiar with the matter” saying that Northfield, Ill.-based Medline has hired Goldman Sachs to manage the process. The people added that the company might alternatively seek… […]
  • Micro to add plant in Costa Rica
    Contract manufacturer Micro today announced plans to open a new plant in Costa Rica. The 32,000 ft² facility will significantly increase Micro’s cleanroom assembly capacity, according to the Somerset, N.J.-based company. It will be located in the Zona Franca Metro business park and is expected to open in late 2021 with operations beginning in 2022.… […]
  • Survey shows solid medical device industry performance despite pandemic
    By Stewart Eisenhart, Emergo Group Medical device and IVD manufacturers report healthy performance over the course of 2020, but also faced significant operational and regulatory challenges related to the coronavirus pandemic. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks by MassDevice · How Zimmer Biomet is competing in ortho’s data race; Do medical devices carry physics-based biases?

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS